Pilot Study: Feasibility of HCV RNA Diagnostic Testing via Dried Blood Spot in Non-Clinical Settings in New York State

Bureau of Hepatitis Health Care, AIDS Institute
The Challenge

30-40% of those with a reactive HCV antibody test do not complete the testing algorithm.
Challenges to Traditional HCV RNA Testing

- Requires venipuncture blood sample
  - Clinical setting with staff trained in phlebotomy
  - Invasive procedure
  - Requires additional time with the client
  - May be difficult to access veins on PWID
  - Potential trigger for PWID

- Requires specific preparation, handling and storage of samples

- Specimen shipping restrictions, including:
  - Geographic limitations
  - Temperature control
  - Limited transit time
  - Special packaging required
Dried Blood Spot (DBS) Sampling

Blood from a finger stick is placed on a filter paper card that is allowed to air dry for at least 4 hours.
Advantages of Dried Blood Spot Sampling

• Used extensively for other diagnostic testing and disease surveillance
• Less invasive procedure
• Requires minimal blood volume (4 spots of 30-100µl each)
• Limited training necessary
• Longer window of time for transport (15 days vs 3-7 days)
• Sample stability
Pilot Study Opportunity

- Wadsworth Center, Bloodborne Viruses Laboratory (BVL) developed and validated HCV RNA test using DBS samples
- Collaboration between Wadsworth and the BHHC on a six month IRB-approved pilot using DBS
- Aim to collect 300 test specimens across six Programs enrolled in the NYS Rapid Testing Program:
  - 3 Community Based Organizations (CBO)
  - 2 Syringe Exchange Programs (SEP)
  - 1 Hospital-Based Clinic
Pilot Objectives

• Evaluate the feasibility of dried blood spot specimen collection for HCV RNA testing in conjunction with HCV rapid antibody testing in nonclinical settings

• Assess quality of dried blood spot specimens submitted from non-clinical settings to ensure they meet specimen acceptance criteria for HCV RNA testing.

• Evaluate staff experience and client experience with dried blood spot collection process
Community Partners in NYC Participating in the DBS Pilot

• Community Health Action of Staten Island (CHASI)

• Mount Sinai Internal Medicine

• VOCAL NY
Pilot Implementation

- NYSDOH AIDS Institute provided:
  - DBS collection and shipping supplies
  - Training for staff
  - Analysis of staff and client surveys

- Wadsworth Center BVL provided:
  - HCV RNA testing
  - Specimen tracking and reporting through Clinical Laboratory Information Management System (CLIMS)
DBS Training
Interim Pilot Outcomes

• 284 samples submitted as of August 31, 2019
  – 13 of 154 samples, quality precluded analysis
  – 16 of 154 samples, yielded indeterminate result
  – 255 of 154 samples, provided diagnostic outcomes
• Programs report DBS being well-received by clients and testing staff
Challenges and Lessons Learned

• Frequent staff turnover
  – Need for repeat training and enhanced supervision

• Poor sample quality
  – Reinforce messages about smears, layering of blood, alcohol residue

• Logistical considerations
  – Consider higher volume of testing and the implication on transportation from the field as well as the need for space to allow samples to dry appropriately
Challenges and Lessons Learned

• Insufficient sample due to incomplete cards/circles
  – Revised pilot guidance to promote completion of 4 circles
  – Developed a size guide tool to help staff assess adequacy of sample size
  – Recommended use of high-flow lancets to ensure adequate sample size and reduce client discomfort.

• Difficult specimen collection during winter weather in outreach sites
  – Used hand warmers to increase circulation
  – Used hand sanitizer to encourage participants to massage hands and increase blood flow
Challenges and Lessons Learned

• Time management when incorporating DBS into testing
  – Programs highlighted the importance of understanding client’s time constraints.
  – To reduce time, some programs collected the DBS card first, then the OraQuick® HCV Rapid Antibody test to ensure adequate sample collection on a single fingerstick.
  – Some programs opted to give clients the option of conducting the antibody test and DBS simultaneously or sequentially.
Limitations

• DBS for HCV RNA testing is not commercially available.

• Wadsworth Center used a CLEP approved laboratory-developed test for qualitative detection of HCV RNA. For DBS, the limit of detection is higher than plasma samples.

• DBS processing adds steps to the current laboratory process. At this time, Wadsworth has limited capacity to process a high volume of DBS specimens.

• Venipuncture RNA testing remains the gold standard for care. DBS should enhance, not replace venipuncture testing.
Conclusion

• Additional tool with potential to increase client acceptance of HCV diagnostic testing, particularly for those who are:
  – Reluctant to accept an off-site referral
  – Tested in non-clinical outreach settings without access to phlebotomy
  – Difficult to draw blood on
• DBS offers simplified specimen packaging and shipping
• Potential application for future use for research projects and public health outbreak investigations.
Acknowledgements

• Dr. Monica Parker
• Renee Hallack, BS
• Wadsworth Center, Bloodborne Viruses Laboratory Staff

Questions for NYS HCV RTP Staff
Phone: 518-486-6806

Melissa Frisbie, MPH
melissa.frisbie@health.ny.gov

Tracey Knickerbocker, MA
tracey.knickerbocker@health.ny.gov